PRIME Clinical Impact
Treating 10 hypertensive patients with type 2 diabetes and microalbuminuria with irbesartan 300 mg for 2 years would prevent one patient from developing overt diabetic nephropathy within 2 years
Treating 15 hypertensive patients with type 2 diabetes and proteinuria with irbesartan for 3 years would prevent one patient from developing a doubling of serum creatinine, ESRD or death within 3 years
- Potential cost savings of $2.5 billion within 3 years